Evotec extends ongoing collaboration with CHDI Foundation

30-Oct-2012 - Germany

Evotec AG announced that CHDI Foundation, Inc. (CHDI), a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease (HD), has extended its collaboration with Evotec until the end of 2015. This contract extension could be worth up to USD 41 million in research payments for Evotec.

The collaboration takes full advantage of Evotec's integrated drug discovery platform and its proficiency in neurological research, including its expertise in medicinal chemistry, in vitro and in vivo pharmacology, and compound management. Evotec and CHDI entered into this alliance in March 2006, and since then the collaborative relationship has grown significantly. The extension of this collaboration further validates Evotec's broad expertise in CNS drug discovery and development.

'We are delighted that CHDI, an organisation dedicated solely to the quest to discover novel drugs against Huntington's disease, continues to work in partnership with Evotec,' said Dr Mario Polywka, Chief Operating Officer of Evotec. 'This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec's platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts.'

'CHDI partners with a global network of investigators from the academic, biopharmaceutical, and service sectors to execute our drug discovery and development efforts,' said Dr Robert Pacifici, Chief Scientific Officer at CHDI. 'Evotec represents one of our largest and longest standing relationships with a contract research organisation. We are delighted that, with the renewal of our contract, CHDI and Evotec will be able to continue our productive interactions and drive our therapeutic programs forward.'

https://www.bionity.com/en/news/140292/evotec-extends-ongoing-collaboration-with-chdi-foundation.html